Xbira 250mg Tablet (Abiraterone Acetate 250mg)

What is Xbira 250mg Tablet (Abiraterone Acetate 250mg)?

Xbira 250mg Tablet is an oral oncology drug whose active ingredient is abiraterone acetate, a potent inhibitor of CYP17A1 enzyme that drives androgen synthesis. By blocking this pathway, the medication reduces circulating testosterone that fuels the growth of castration-resistant prostate cancer. The tablet is taken once daily, usually in the morning, and must be accompanied by a low-dose corticosteroid such as prednisone to mitigate mineralocorticoid excess. Absorption is rapid, reaching peak plasma concentrations within two hours, and the drug is metabolized primarily by hepatic CYP3A4 enzymes. Food can increase exposure, so clinicians often advise taking the tablet on an empty stomach. The elimination half-life extends to about 12 days, supporting steady-state levels with daily dosing.

Key features

• Mechanism of action — selective CYP17A1 inhibition reduces androgen production.
• Dosage form — 250 mg film-coated tablet for once-daily oral administration.
• Combination therapy — recommended with prednisone to control side-effects.
• Clinical evidence — proven survival benefit in phase III trials for metastatic prostate cancer.
• Safety profile — requires monitoring of liver enzymes, potassium, and blood pressure.
• Regulatory status — FDA-approved prescription medication.

Who is Xbira 250mg Tablet (Abiraterone Acetate 250mg) for?

The drug is indicated for men with advanced or metastatic prostate cancer who have progressed despite androgen-deprivation therapy. It is also considered for patients who cannot tolerate chemotherapy or who need an oral alternative to intravenous regimens. Physicians may prescribe it for off-label uses only after careful risk-benefit analysis. Patients must undergo baseline liver function tests and periodic electrolyte checks, as the drug can cause hypertension, hypokalemia, and fluid retention. Education on recognizing signs of adrenal insufficiency is essential, given the concomitant steroid requirement.

How does Xbira 250mg Tablet (Abiraterone Acetate 250mg) compare?

Compared with traditional chemotherapy agents, Xbira offers an oral route, fewer infusion-related complications, and a distinct side-effect spectrum focused on hormonal and hepatic parameters. Relative to other androgen-synthesis inhibitors, its 250 mg strength provides a convenient once-daily schedule, though dose adjustments may be needed for hepatic impairment. From a cost perspective, oral administration reduces hospital visits, but the medication price can be substantial, often offset by insurance coverage or patient assistance programs. Preference for a pill over infusion aligns with many patients' desire for convenience and autonomy.